3401
TEIJIN LIMITED
帝人株式会社Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses in Japan and internationally. The company provides aramid fibers; glass and carbon fibers, composite materials, infusion resins, adhesives, fillers and resin films, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. It also offers PC resins, polyphenylene sulfide resins, molded parts, flame retardant, and additives; lightweight glass and carbon fiber reinforced composites for automotive applications; and polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. In addition, the company provides pharmaceuticals for bone and joint, respiratory, cardiovascular and metabolic, and other diseases; home oxygen therapy, non-invasive positive pressure ventilation, and sleep disordered breathing related devices, as well as sonic accelerated fracture healing system and community-based integrated care system businesses. Further, the company provides implantable medical devices and regenerative medical products. Additionally, it develops and implements engineering solutions for various issues, such as environmental pollution, energy supply stability, and aging-related workforce population decline. Teijin Limited was incorporated in 1918 and is headquartered in Tokyo, Japan.
Price
¥1,652
Market Cap
¥318.3B
Ent. Value
¥525.3B
Net Debt
−¥207.0B
Shares Out.
192.7M
P / E
—
EV / EBIT
—
P / Book
0.87×
P / NCAV
N/M
Div. Yield
1.51%
Financials
| Metric |
FY 2025
TDnet |
FY 2024
TDnet |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|---|
| Net Sales | ¥873.2B | ¥873.2B | ¥1,032.8B | ¥1,018.8B | ¥926.1B |
| Cost of Sales | ¥711.2B | ¥711.2B | ¥757.0B | ¥770.6B | ¥655.0B |
| Gross Profit | ¥162.0B | ¥162.0B | ¥275.8B | ¥248.1B | ¥271.0B |
| SG&A | ¥231.3B | ¥231.3B | ¥262.2B | ¥235.3B | ¥226.8B |
| Operating Income | ¥-70.7B | ¥-70.7B | ¥13.5B | ¥12.9B | ¥44.2B |
| Non-Operating Income | — | ¥4.1B | ¥21.7B | ¥9.2B | ¥15.1B |
| Dividend Income | — | — | ¥1.1B | ¥1.3B | ¥1.2B |
| Interest Income | — | ¥2.9B | ¥2.6B | ¥1.3B | ¥468M |
| Non-Operating Expenses | — | ¥11.4B | ¥19.7B | ¥12.9B | ¥9.6B |
| Interest Expense | — | ¥10.4B | ¥10.8B | ¥7.1B | ¥3.3B |
| Ordinary Income | ¥-70.7B | ¥-71.8B | ¥15.6B | ¥9.1B | ¥49.7B |
| Pre-tax Income | ¥-74.1B | ¥-74.1B | ¥28.4B | ¥-1.5B | ¥44.1B |
| Income Taxes | — | — | ¥14.8B | ¥14.3B | ¥18.1B |
| Current Tax | — | — | ¥24.9B | ¥12.1B | ¥14.8B |
| Deferred Tax | — | — | ¥-10.1B | ¥2.2B | ¥3.3B |
| Net Income (owners) | ¥-88.0B | ¥-88.0B | ¥10.6B | ¥-17.7B | ¥23.2B |
| Minority Interest | — | ¥2.0B | ¥3.0B | ¥1.9B | ¥2.8B |
| Comprehensive Income | — | ¥29.1B | ¥36.9B | ¥-1.9B | ¥46.0B |
| EBITDA | ¥-10.4B | ¥-10.4B | — | — | — |
| Goodwill Amort. (J-GAAP) | — | — | ¥1.9B | ¥3.8B | ¥4.6B |
| EPS | ¥-456.33 | ¥-456.33 | ¥55.07 | ¥-92.04 | ¥120.58 |
| Shares Outstanding | — | 192.7M | 192.6M | 192.3M | 192.1M |
| Shares Issued (total) | — | 198.0M | 198.0M | 198.0M | 198.0M |
| Treasury Shares | — | 5.2M | 5.4M | 5.6M | 5.8M |